Pyrimethamine Elicits Antitumor Effects on Prostate Cancer by Inhibiting the p38-NF-κB Pathway

• Main Authors: Xumin Zhou (Author), Jinming Zhang (Author), Xiaoping Hu (Author), Peiqing He (Author), Jianyu Guo (Author), Jun Li (Author), Tian Lan (Author), Jumei Liu (Author), Lilan Peng (Author), Hua Li (Author)
• Format: Book
• Published: Frontiers Media S.A., 2020-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Since incurable castration-resistant prostate cancer (CRPC) inevitably develops following treatment with androgen deprivation therapy, there is an urgent need to devise new therapeutic strategies to treat this cancer. Pyrimethamine, an FDA-approved antimalarial drug, is known to exert an antitumor a...